Avenga
Driving Pharma Excellence Through Custom Software Solutions

The journey of bringing a pharmaceutical and life sciences product from concept to market is a complex endeavour. It requires the collaboration of numerous partners, which often leads to a fragmented and inefficient operational workflow, which poses significant challenges in maintaining effective oversight and ensuring the product progresses in a timely manner throughout its lifecycle.

This is where Avenga, a global technology partner, comes to the rescue. With its custom software development (CSD) services, Avenga ensures a smooth transition from product conception to market debut. By digitizing and orchestrating operational processes, companies can realign their efforts towards improving the patient experience, leveraging the power of automation.

It distinguishes itself through its profound expertise in four critical stages—R&D, clinical trial management, pharmacovigilance and product commercialisation. Each phase is a cornerstone in a product’s journey to market readiness, necessitating the best approaches to surmount the distinct challenges they pose. Avenga’s GxP-compliant software development services help clients ensure that each product achieves market success but adheres to the highest standards of safety. Avenga stands out for developing its client’s clinical trial management systems (CTMS) that enhance the coordination, monitoring and documentation of clinical trials—the bedrock of new pharmaceutical developments. Leveraging advanced data science tools, the company enables the extraction of actionable insights from vast datasets, facilitating the selection of ideal clinical trial candidates through criteria beyond conventional rule engines.

“Our software facilitates the clients in their advanced cohort selection techniques, heightening the quality and dependability of trial outcomes and paving the way for smoother, more effective clinical trial processes. This, in turn, accelerates the introduction of safe and efficacious drugs to the market,” says Iurii Odnorogov, VP of Engagement at Avenga.
As products progress from clinical trials to widespread application, the importance of monitoring for safety escalates.Avenga’s expertise in pharmacovigilance ensures thorough tracking of drug performance, confirming that medications fulfil their intended efficacy as per manufacturers’ claims and comply with regulatory criteria set forth by authorities like the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

This expertise affords pharmaceutical companies’ critical insights into their products’ real-world performance and safeguards product integrity. By effectively checking and analysing post-market data, clients can identify any adverse reactions or safety issues linked to medications, allowing swift action and preventative measures to secure patient safety.

The software’s advanced reporting capabilities help clients detect adverse drug reactions, which might otherwise remain under the radar of medical authorities and pharmaceutical companies. A data science-based approach scrutinises social media for mentions of reactions related to specific drugs. This innovative system alerts pharmaceutical companies to potential issues through early warning signals, enabling them to initiate investigations and proactively take corrective actions, circumventing the need for widespread public complaints or legal recourse.

To ensure the successful market entry of these drugs, it’s crucial for companies to deploy effective marketing strategies. With Avenga on their side, clients can easily develop commercialisation software systems to transform this requirement into reality. Designed with the unique needs of pharmaceutical companies in mind, this system functions akin to omnichannel engagement that combines the functionality of both customer relationship management (CRM) and marketing platforms, specifically tailored for the pharmaceutical sector.

A testament to Avenga’s innovative approach is its partnership with Klara, which aimed to transform patient engagement and streamline medical communications and data handling. The collaboration resulted in the creation of a HIPAA-compliant software tool that facilitates comprehensive digital medical examinations and consultations. This platform, designed with a user-friendly interface, enhances communication efficiency, centralises patient interactions and automates routine outreach efforts, showcasing Avenga’s capability to deliver tailored healthcare solutions that meet today’s digital demands.

Unlike many of its contemporaries, Avenga adopts a specialised focus rather than casting a wide net across numerous industries and services. This strategic concentration is supported by a global workforce of approximately 7,000 professionals dedicated to mastering select verticals through deep in-house expertise and extensive industry experience. Not just that, the company is on the cusp of a transformative merger with Qinshift, a global technology leader noted for its significant European footprint. This strategic merger is anticipated to catapult the combined entity to a leading position on the global stage.

Its strategic positioning across various time zones, including delivery centres in Argentina that align with U.S. time zones, ensures that it can offer uninterrupted collaboration and support to a global clientele. This geographical diversity, combined with its substantial scale and domain expertise, positions Avenga to handle intricate custom software development projects, maximising value through focused research, development and marketing initiatives.